CN111467254A - 一种抗衰老冻干粉组合物及其制备方法 - Google Patents
一种抗衰老冻干粉组合物及其制备方法 Download PDFInfo
- Publication number
- CN111467254A CN111467254A CN202010304724.0A CN202010304724A CN111467254A CN 111467254 A CN111467254 A CN 111467254A CN 202010304724 A CN202010304724 A CN 202010304724A CN 111467254 A CN111467254 A CN 111467254A
- Authority
- CN
- China
- Prior art keywords
- parts
- oligopeptide
- carnosine
- aging
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 239000000843 powder Substances 0.000 title claims abstract description 30
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 30
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 30
- 108010087806 Carnosine Proteins 0.000 claims abstract description 27
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 24
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 24
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 24
- 229940044199 carnosine Drugs 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 15
- 229930195725 Mannitol Natural products 0.000 claims abstract description 15
- 239000000594 mannitol Substances 0.000 claims abstract description 15
- 235000010355 mannitol Nutrition 0.000 claims abstract description 15
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 6
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 6
- 239000008176 lyophilized powder Substances 0.000 claims description 12
- 238000001291 vacuum drying Methods 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 230000002087 whitening effect Effects 0.000 abstract description 7
- 230000003020 moisturizing effect Effects 0.000 abstract description 6
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 3
- 206010000496 acne Diseases 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 238000007254 oxidation reaction Methods 0.000 abstract description 3
- 238000002845 discoloration Methods 0.000 abstract description 2
- 230000002779 inactivation Effects 0.000 abstract description 2
- 230000001590 oxidative effect Effects 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 20
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000037067 skin hydration Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 229940067599 ascorbyl glucoside Drugs 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种抗衰老冻干粉组合物及其制备方法,该抗衰老冻干粉组合物包括如下质量份的原料:水90~95份、甘露糖醇4~6份、肌肽0.1~1份、凝血酸1~3份、寡肽‑10.1~1份。本发明在冻干粉中同时加入了肌肽、凝血酸和寡肽‑1的活性因子,并将肌肽、凝血酸和寡肽‑1的比例控制在一定范围内,可有效利用肌肽的抗氧化能力避免凝血酸氧化变色失活,同时肌肽、凝血酸和寡肽‑1三者协同作用共同发挥出优异的抗衰老、保湿和美白效果,同时具有良好的肌肤修复、祛疤痕、防晒、防粉刺效果。
Description
技术领域
本发明属于化妆品技术领域,尤其涉及一种抗衰老冻干粉组合物及其制备方法。
背景技术
冻干粉是在无菌环境下将药液冷冻成固态,抽真空将水分升华干燥而成的无菌粉注射剂,主要具有皮肤修复、提高皮肤光滑度等美容功能。一般的冻干粉原料由生长因子和保湿剂组成,如CN110292537A公开的冻干粉包括水80~92%、寡肽-13~10%、甘露糖醇和5~10%。虽然该冻干粉具有一定的肌肤修复功能,但是抗衰老、保湿和美白效果较弱。CN110227038A公开的冻干粉,包含以下按质量百分计算的组分:凝血酸:1~3%,烟酰胺:1~5%,甘露糖醇:0.6~4.6%,抗坏血酸葡糖苷:0.5~2%,余量为水。由于凝血酸、烟酰胺、和抗坏血酸葡糖苷容易变色失活、利用率不高、容易过敏,CN110227038A的冻干粉需要采用及其复杂繁琐的制备工艺。因此,亟需一种同时具有优异抗衰老、保湿和美白效果,且制备工艺简单的冻干粉。
发明内容
本发明的目的在于提供一种抗衰老冻干粉组合物及其制备方法,该组合物同时具有优异抗衰老、保湿和美白效果。
本发明采用的技术方案为:
一种抗衰老冻干粉组合物,包括如下质量份的原料:水90~95份、甘露糖醇4~6份、肌肽0.1~1份、凝血酸1~3份、寡肽-10.1~1份。
所述肌肽、凝血酸和寡肽-1的质量比为(0.1~1):2:(0.1~1)。
优选地,所述抗衰老冻干粉组合物,包括如下质量份的原料:水92份、甘露糖醇5份、肌肽0.5份、凝血酸2份、寡肽-10.5份。
所述寡肽-1的分子量为300~400。
一种抗衰老冻干粉组合物的制备方法,包括如下步骤:
(1)按配方称取物料;
(2)将水、甘露糖醇、肌肽、凝血酸和寡肽-1混合均匀后进行真空干燥。
所述真空干燥的温度为-45~35℃。
所述真空干燥的压强为0~20Pa。
所述真空干燥的时间为2~20h。
所述真空干燥方法为:
1)降温至-40℃,至样品完全结冰;
2)继续降温至-45℃,然后抽真空至0~20Pa;
3)逐渐升温,在-40~-20℃保持1~2h,在-20~-10℃保持2~4h,在-10~1℃保持4~5h,至冻干水纹线消失;然后在-1~10℃保持4~5h,在10~20℃保持4~5h,在20~33℃,保持4~5h;最后升温至33~35℃,抽真空1~2h。
肌肽是一种由β-丙氨酸和L-组氨酸两种氨基酸组成的二肽,具有很强的抗氧化能力,同时可均衡肌肤营养物质分配、维持肌肤正常新陈代谢,从而净化肌肤,影响皮肤质感、肤色和外形,提升肌肤自身抵抗力及自愈力。
相对于现有技术,本发明在冻干粉中同时加入了肌肽、凝血酸和寡肽-1等活性因子,并将肌肽、凝血酸和寡肽-1的比例控制在一定范围内,可有效利用肌肽的抗氧化能力避免凝血酸氧化变色失活,同时肌肽、凝血酸和寡肽-1三者协同作用共同发挥出优异的抗衰老、保湿和美白效果,还具有良好的肌肤修复、祛疤痕、防晒、防粉刺效果。
具体实施方式
下面结合实施例,进一步说明本发明的技术方案。
实施例1
本实施例提供一种抗衰老冻干粉组合物,包括如下表1的原料:
表1.抗衰老冻干粉组合物的原料及其配比
原料代号 | 中文化学名 | 商品名 | 配比/份 |
ROT021 | 水 | Pure water 30c | 92 |
RPW053 | 甘露糖醇 | 甘露糖醇 | 5 |
RAC327 | 肌肽 | 二肽 | 0.5 |
RAC019 | 凝血酸 | Tranexamic Acid | 2 |
RAC340 | 寡肽-1(分子量348.38) | 寡肽-1 | 0.5 |
本实施例的抗衰老冻干粉组合物的制备方法包括如下步骤:
(1)按配方称取物料;
(2)将水、甘露糖醇、肌肽、凝血酸和寡肽-1在室温下依次加入不锈钢锅中搅拌溶解均匀,然后将混合物按照所需量灌装入西林瓶中;
(3)将样品摆放到冻干粉机中进行真空干燥。具体地,开启冷冻开关,降温至-40℃,至样品完全结冰;开启冷阱降温开关,降温至-45℃;启动抽真空机,打开连接阀,打开平衡阀,使冷阱真空度保持在10Pa左右;打开样品箱升温开关,逐渐升温,-30℃保持2h;-15℃保持3h;-5℃保持4h,观察冻干水纹线消失;5℃保持4h;15℃保持4h;25℃保持4h;升温至35℃,关闭平衡阀,抽真空2h;然后压盖,关闭加热、关闭抽真空装置,打开排气阀,取出样品压盖。
实施例2
本实施例提供一种抗衰老冻干粉组合物,包括如下表2的原料:
表2.抗衰老冻干粉组合物的原料及其配比
原料代号 | 中文化学名 | 商品名 | 配比/份 |
ROT021 | 水 | Pure water 30c | 91 |
RPW053 | 甘露糖醇 | 甘露糖醇 | 5 |
RAC327 | 肌肽 | 二肽 | 1 |
RAC019 | 凝血酸 | Tranexamic Acid | 2 |
RAC340 | 寡肽-1(分子量348.38) | 寡肽-1 | 1 |
本实施例的抗衰老冻干粉组合物的制备方法同实施例1。
对比例1
本对比例提供一种冻干粉组合物,相较实施例1和实施例2主要增加了肌肽和寡肽-1的用量,改变了肌肽、凝血酸和寡肽-1的三者的比例,具体包括如下表3的原料:
表3.冻干粉组合物的原料及其配比
原料代号 | 中文化学名 | 商品名 | 配比/份 |
ROT021 | 水 | Pure water 30c | 89 |
RPW053 | 甘露糖醇 | 5 | |
RAC327 | 肌肽 | 二肽 | 2 |
RAC019 | 凝血酸 | Tranexamic Acid | 2 |
RAC340 | 寡肽-1(分子量348.38) | 寡肽-1 | 2 |
本对比例的冻干粉组合物的制备方法同实施例1。
对比例2
本对比例与实施例1不同之处在于省去肌肽。
对比例3
本对比例与实施例1不同之处在于省去凝血酸。
对比例4
本对比例与实施例1不同之处在于省去寡肽-1。
性能测试:
(1)抗氧活性
对实施例1、2和对比例的冻干粉组合物抗氧活性[AOA,AOA可用滴定100g所分析的物质消耗的库仑量(kCb/100g)来表示],结果如表4所示:
表4.冻干粉组合物抗氧活性
根据表4可知,本发明制得的冻干粉组合物的AOA值明显高于对比例,表明本发明的保养品具有很好的抗氧活性,可有效的清除自由基,实现抗衰老的目的。
(2)皮肤肤色
使用德国Courage Khazaka(CK)公司生产的皮肤颜色测试仪Colorimeter CL400对皮肤肤色L值进行测试,通过测量产品使用前后皮肤L值的变化,评估冻干粉组合物对皮肤透亮度的影响。
具体地,选取三组起始L值(使用保养品前的皮肤肤色L值)平均值相同的志愿者进行受试,每组10人。受试者分组每日早晚在脸部涂抹样品两次,连续涂抹四周。经四周后,测试受试者的皮肤肤色L值,结果取平均值,结果如表5:
表5.保养品对皮肤肤色的影响
实施例1 | 实施例2 | 对比例1 | 对比例2 | 对比例3 | 对比例4 | |
0周 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 | 45.0 |
4周 | 60.1 | 59.4 | 54.3 | 52.5 | 53.6 | 53.1 |
根据表5可知,本发明制得的保养品的皮肤肤色L值明显高于对比例,能够更有效地提亮肤色,实现美白目的。
(3)皮肤水合度
测定皮肤水合度,使三组受试者的起始平均值相同,每组10人,周期为四周,结果取平均值,如表6:
表6.保养品对皮肤水合度的影响
实施例1 | 实施例2 | 对比例 | 对比例2 | 对比例3 | 对比例4 | |
0周 | 23.0 | 23.0 | 23.0 | 23.0 | 23.0 | 23.0 |
4周 | 39.8 | 38.9 | 35.1 | 34.9 | 34.8 | 34.2 |
根据表6可知,使用四周本发明制得的保养品后,皮肤水合度明显高于对比例,能够更好的锁住水分,具有更好的保湿效果。
另外,受试者反映,本发明的冻干粉组合物还能够修复肌肤、祛疤痕,具有防晒效果,防止长粉刺等效果。
综上所述,本发明通过在冻干粉中同时加入了肌肽、凝血酸和寡肽-1等活性因子,能够使冻干粉同时具有抗衰老、保湿和美白效果。当将肌肽、凝血酸和寡肽-1的质量比例控制在(0.1~1):(1~3):(0.1~1)范围,尤其是(0.1~1):2:(0.1~1)范围时冻干粉的抗衰老、保湿和美白效果更显著。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (9)
1.一种抗衰老冻干粉组合物,其特征在于:包括如下质量份的原料:水90~95份、甘露糖醇4~6份、肌肽0.1~1份、凝血酸1~3份、寡肽-10.1~1份。
2.根据权利要求1所述抗衰老冻干粉组合物,其特征在于:所述肌肽、凝血酸和寡肽-1的质量比为(0.1~1):2:(0.1~1)。
3.根据权利要求1所述抗衰老冻干粉组合物,其特征在于:所述抗衰老冻干粉组合物,包括如下质量份的原料:水92份、甘露糖醇5份、肌肽0.5份、凝血酸2份、寡肽-10.5份。
4.根据权利要求1~3任意一项所述抗衰老冻干粉组合物,其特征在于:所述寡肽-1的分子量为300~400。
5.一种权利要求1~4任意一项所述抗衰老冻干粉组合物的制备方法,其特征在于:包括如下步骤:
(1)按配方称取原料;
(2)将水、甘露糖醇、肌肽、凝血酸和寡肽-1混合均匀后进行真空干燥。
6.根据权利要求5所述制备方法,其特征在于:所述真空干燥的温度为-45~35℃。
7.根据权利要求5所述制备方法,其特征在于:所述真空干燥的真空度为0~20Pa。
8.根据权利要求5所述制备方法,其特征在于:所述真空干燥的时间为2~20h。
9.根据权利要求5~8任意一项所述制备方法,其特征在于:所述真空干燥方法为:
1)降温至-40℃,至样品结冰;
2)继续降温至-45℃,然后抽真空至真空度为0~20Pa;
3)逐渐升温,在-40~-20℃保持1~2h,在-20~-10℃保持2~4h,在-10~1℃保持4~5h,至冻干水纹线消失;然后在-1~10℃保持4~5h,在10~20℃保持4~5h,在20~33℃,保持4~5h;最后升温至33~35℃,抽真空1~2h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010304724.0A CN111467254A (zh) | 2020-04-17 | 2020-04-17 | 一种抗衰老冻干粉组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010304724.0A CN111467254A (zh) | 2020-04-17 | 2020-04-17 | 一种抗衰老冻干粉组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111467254A true CN111467254A (zh) | 2020-07-31 |
Family
ID=71754361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010304724.0A Pending CN111467254A (zh) | 2020-04-17 | 2020-04-17 | 一种抗衰老冻干粉组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111467254A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112043621A (zh) * | 2020-09-15 | 2020-12-08 | 浙江宜格企业管理集团有限公司 | 一种具有抗衰效果的无防腐多肽组合物 |
CN113171318A (zh) * | 2021-05-07 | 2021-07-27 | 广州欣蔓化妆品有限公司 | 一种具有保湿美白舒缓修复的冻干粉制剂及制备方法 |
-
2020
- 2020-04-17 CN CN202010304724.0A patent/CN111467254A/zh active Pending
Non-Patent Citations (1)
Title |
---|
安婕妤化妆品科技股份有限公司: "瑞特莲恩胜肽冻干粉组合-胜肽冻干粉+胜肽精华液"", 《国产非特殊用途化妆品备案信息服务平台》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112043621A (zh) * | 2020-09-15 | 2020-12-08 | 浙江宜格企业管理集团有限公司 | 一种具有抗衰效果的无防腐多肽组合物 |
CN112043621B (zh) * | 2020-09-15 | 2022-10-14 | 杭州时光肌生物科技有限公司 | 一种具有抗衰效果的无防腐多肽组合物 |
CN113171318A (zh) * | 2021-05-07 | 2021-07-27 | 广州欣蔓化妆品有限公司 | 一种具有保湿美白舒缓修复的冻干粉制剂及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105748400B (zh) | 一种酵母多肽冻干粉面膜组合及其制作方法 | |
CN111467254A (zh) | 一种抗衰老冻干粉组合物及其制备方法 | |
CN112043621B (zh) | 一种具有抗衰效果的无防腐多肽组合物 | |
CN113842334B (zh) | 一种促进皮肤多维防御和修复的组合物及其制备方法 | |
CN111603434A (zh) | 一种改善皮肤皱纹的组合物及其化妆品 | |
CN115607499A (zh) | 一种用于抗皱紧致的人参灵芝多肽组合物及其应用 | |
CN111544323A (zh) | 一种用于肌肤修复的组合物及其制备方法和应用 | |
CN113018228A (zh) | 一种抗衰老组合物、面霜及其制备方法 | |
CN113499279B (zh) | 一种美白修复抗衰冻干小奶片及其制备工艺 | |
CN109330929B (zh) | 一种银耳发酵提取物的制备方法及其在化妆品中的应用 | |
CN109077973B (zh) | 一种两剂碳酸发泡面膜及其制备方法与使用方法 | |
CN108888527B (zh) | 一种改善皮肤干燥、敏感的冻干粉剂及其制备方法 | |
CN114886785B (zh) | 一种三元冻干组合物及其在冻干制剂中的应用 | |
CN113730289B (zh) | 一种具有多重修护功效的眼唇护理组合物及其应用 | |
CN114432178A (zh) | 一种皮肤微生态平衡组合物及其制备方法与应用 | |
CN113576944B (zh) | 冻干球及其制备方法、护肤品 | |
KR20200066930A (ko) | 항산화 활성을 갖는 대황 추출물을 함유하는 화장료 조성물 | |
CN104434557A (zh) | 一种具有抗氧化作用的肽组合物及其方法与应用 | |
CN115252464A (zh) | 水溶性活性物处理粉体及其制备方法和应用 | |
CN114392211A (zh) | 一种二裂酵母冻干粉组合物及其制备方法 | |
KR102199934B1 (ko) | 황련해독탕의 김치유산균 발효물을 함유하는 여드름 개선용 화장료 조성물 | |
KR20170136212A (ko) | 줄기세포 성장인자를 포함하는 동결건조 조성물 및 그 제조방법 | |
CN110623901A (zh) | 一种美容用冻干粉及生产工艺 | |
KR101289062B1 (ko) | 인태반 유래 성장인자 및 사이토카인들을 함유한 유사 인태반 조성물 및 이의 화장품 용도 | |
CN112120984B (zh) | 一种保湿、亮泽肌肤的组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200731 |
|
RJ01 | Rejection of invention patent application after publication |